Malin Corporation | MLC - Betriebsaufwand

Aktienkurs
7.70
Täglich Wechseln
0.10 1.32%
Monatlich
1.32%
Jährlich
-21.43%
Q1 Prognose
7.47




Betriebsaufwand Veränderung Datum
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alaunos Therapeutics USD 1.19M 148K 2025-09
ALKERMES USD 326.44M 1.41B 2025-12
Avita Medical AUD 28.02M 1.55M 2025-12
Dianthus Therapeutics USD 69.82M 29.14M 2025-12
Eurofins Scientific SE EUR 3.29B 462.3M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
IQVIA Holdings USD 1.69B 4.47B 2025-12
Lonza CHF 2.9B 184M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Moderna USD 1.54B 259M 2025-12
Organon & Co USD 906M 362M 2025-09
Ovoca Bio EUR 5.65M 3.45M 2022-06
Revvity USD 626.22M 25.62M 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
Viatris USD 3.86B 335.7M 2025-12
Xeris Pharmaceuticals USD 69.03M 1.38M 2025-12